StockNews.com Begins Coverage on Fresenius Medical Care (NYSE:FMS)

Research analysts at StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Sunday. The brokerage set a “strong-buy” rating on the stock.

Separately, Truist Financial lowered their price target on shares of Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating on the stock in a research report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Fresenius Medical Care has a consensus rating of “Hold” and an average target price of $22.00.

Fresenius Medical Care Stock Performance

NYSE FMS opened at $20.27 on Friday. The business has a 50 day moving average price of $19.57 and a 200 day moving average price of $19.92. The company has a market capitalization of $11.89 billion, a P/E ratio of 22.77, a PEG ratio of 1.09 and a beta of 0.90. Fresenius Medical Care has a 1-year low of $16.37 and a 1-year high of $22.76. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The business had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.28 billion. Sell-side analysts expect that Fresenius Medical Care will post 1.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wulff Hansen & CO. raised its position in shares of Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after buying an additional 325,439 shares during the last quarter. Triasima Portfolio Management inc. acquired a new stake in shares of Fresenius Medical Care during the first quarter worth $1,293,000. Corient Private Wealth LLC boosted its holdings in shares of Fresenius Medical Care by 164.6% during the fourth quarter. Corient Private Wealth LLC now owns 66,134 shares of the company’s stock worth $1,378,000 after purchasing an additional 41,139 shares during the last quarter. Veracity Capital LLC grew its position in shares of Fresenius Medical Care by 172.2% in the first quarter. Veracity Capital LLC now owns 53,023 shares of the company’s stock valued at $1,022,000 after purchasing an additional 33,543 shares during the period. Finally, Legacy Wealth Asset Management LLC acquired a new position in Fresenius Medical Care in the first quarter valued at $584,000. 8.25% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.